title: Bioequivalence study of rofecoxib tablets.
abstract: The study was designed to evaluate the bioavailability of two rofecoxib (CAS 162011-90-7) tablet formulations. Twenty-four healthy male volunteers were administered a 25 mg tablet of the test formulation (Ecrox) containing rofecoxib or the originator product (reference). The trial was performed according to an open, cross-over design with a wash-out period of 7 days. Blood samples were taken up to 72 h post dose, the plasma was separated and the concentrations of rofecoxib were determined by an HPLC method. The mean Cmax were 192.07 ng/mL and 187.35 ng/mL, while the mean AUC0-t were 3613.84 ng x h/mL and 3501.56 ng x h/mL for the test and reference formulations, respectively. The median tmax was 3.75 h for the test tablet and 4.00 h for the reference formulation. The mean t(1/2 el) was 10.66 h and 10.61 h for the test and reference formulation, respectively. Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively. Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively. No significant differences of pharmacokinetic parameters between the two studied formulations were found. The 90% confidence interval for the primary target parameters, i.e. intra-individual ratios of AUC0-t and Cmax of rofecoxib were between 0.99 and 1.10 (AUC0-t) as well as between 0.96 and 1.10 (Cmax) and thus within the acceptance ranges. Concerning the secondary parameter tmax the 90% confidence interval for the intra-individual differences was between -0.25 and 0.25 h. In the light of the present study it can be concluded that the two evaluated rofecoxib formulations, i.e. test tablets of rofecoxib and a reference preparation are bioequivalent in terms of the rate and extent of absorption.
authors.affiliation: Cooperative Clinical Drug Research and Development, Neuenhagen, Germany. mail@ccdrdag.com
authors.forename: Rossen
authors.initials: R
authors.lastname: Koytchev
authors.forename: Yildiz
authors.initials: Y
authors.lastname: Ozalp
authors.forename: Aydin
authors.initials: A
authors.lastname: Erenmemisoglu
authors.forename: Mike John
authors.initials: MJ
authors.lastname: van der Meer
authors.forename: Recep Serdar
authors.initials: RS
authors.lastname: Alpan
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D013450:Sulfones; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; D013607:Tablets; C116926:rofecoxib